Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions

Eli Lilly will now offer all approved doses of Zepbound (tirzepatide) single-dose vials, including the 12.5 mg and 15 mg doses, through its LillyDirect Self Pay Pharmacy Solutions, expanding access for patients paying out-of-pocket. Clinical trials showed significant weight loss in adults taking Zepbound, with some patients on the 15 mg dose losing up to 25% of their body weight; the drug is also approved for treating moderate-to-severe obstructive sleep apnea in obese adults. While Zepbound demonstrates efficacy in weight management, it carries warnings regarding potential thyroid tumors and other serious side effects, and should be used with a reduced-calorie diet and increased physical activity.

Analysis

Eli Lilly & Co. (LLY) is expanding patient access to its obesity drug Zepbound (tirzepatide) by making all approved doses, including the newly added 12.5 mg and 15 mg, available in single-dose vials through its LillyDirect Self Pay Pharmacy Solutions. This strategic move targets the self-pay segment, potentially increasing Zepbound's market penetration, particularly as the drug has demonstrated significant efficacy. Clinical trial data highlighted in the announcement showed adults with obesity or overweight taking Zepbound 15 mg experienced an average weight loss of 48 lbs (approximately 21% of body weight), with about one-third losing over 58 lbs (25% weight loss). In a 72-week study of adults without diabetes, average weight loss was 15.0% (34 lbs) for 5 mg, 19.5% (44 lbs) for 10 mg, and 20.9% (48 lbs) for 15 mg, compared to 3.1% (7 lbs) for placebo. Zepbound, the first dual GIP and GLP-1 receptor agonist for obesity, is also FDA-approved for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. The expansion via LillyDirect, a platform designed for direct home delivery and disease management resources, aims to streamline access. However, the announcement also reiterates Zepbound's significant safety warnings, including the risk of thyroid tumors (including medullary thyroid carcinoma), severe stomach problems, kidney and gallbladder issues, pancreatitis, and serious allergic reactions, underscoring the importance of physician oversight and patient awareness of potential adverse effects.

Key Decisions for Investors

• Investors should view the expanded availability of all Zepbound doses via LillyDirect for self-pay patients as a positive catalyst for LLY, potentially accelerating revenue growth in the lucrative obesity market given the drug's strong efficacy.
• Monitor the adoption rate of Zepbound through the LillyDirect platform, particularly in the self-pay segment, as this will be a key indicator of the strategy's success in overcoming access hurdles and driving volume sales.
• Closely track any emerging data or discussions related to Zepbound's side effect profile and patient persistence, as the highlighted serious warnings could influence long-term market share and physician prescribing habits despite its clinical benefits.